Mordechai Grupper1, David P Nicolau. 1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Abstract
PURPOSE OF REVIEW: Skin and soft tissue infections (SSTIs) are prevalent in the obese population, with rising trend expected. Although numerous antibiotics are available for the prevention and treatment of SSTIs, their characterization in obese patients is not a regulatory mandate. Consequently, information that carries importance for optimizing the dosing regimen in the obese population may not be readily available. This review focuses on the most recent pharmacokinetic and pharmacodynamic data on this topic with attention to cefazolin for surgical prophylaxis as well as antibiotics that are active against methicillin-resistant Staphylococcus aureus (MRSA). Moreover, the implications for optimizing SSTIs prevention and treatment in the obese population will also be discussed. RECENT FINDINGS: On the basis of pharmacokinetic/pharmacodynamic considerations, most studies found a perioperative prophylactic cefazolin regimen of 2 g to be reasonable in the case of obese patients undergoing cesarean delivery or bariatric surgery. There is general paucity of data regarding the pharmacokinetic/pharmacodynamic characteristics of antimicrobials active against MRSA in obese patients, especially for the target tissue. Therapeutic drug monitoring has been correlated with pharmacokinetic/pharmacodynamic optimization for vancomycin and teicoplanin, and should be used in these cases. There is more supportive evidence for the use of oxazolidinones (linezolid and tedizolid), daptomycin and lipoglycopeptides (telavancin, dalbavancin and oritavancin) in the management of SSTIs in this population. SUMMARY: The pharmacokinetic/pharmacodynamic approach, which can be used as a basis or supplement to clinical trials, provides valuable data and decision-making tools for optimizing regimens used for both prevention and treatment of SSTIs in the obese population. Important pharmacokinetic/pharmacodynamic characteristics of antibiotics, such as the penetration into the subcutaneous tissue and the probability of reaching the pharmacodynamic, target dictate efficacy, and thus should be taken into account and further investigated.
PURPOSE OF REVIEW: Skin and soft tissue infections (SSTIs) are prevalent in the obese population, with rising trend expected. Although numerous antibiotics are available for the prevention and treatment of SSTIs, their characterization in obesepatients is not a regulatory mandate. Consequently, information that carries importance for optimizing the dosing regimen in the obese population may not be readily available. This review focuses on the most recent pharmacokinetic and pharmacodynamic data on this topic with attention to cefazolin for surgical prophylaxis as well as antibiotics that are active against methicillin-resistant Staphylococcus aureus (MRSA). Moreover, the implications for optimizing SSTIs prevention and treatment in the obese population will also be discussed. RECENT FINDINGS: On the basis of pharmacokinetic/pharmacodynamic considerations, most studies found a perioperative prophylactic cefazolin regimen of 2 g to be reasonable in the case of obesepatients undergoing cesarean delivery or bariatric surgery. There is general paucity of data regarding the pharmacokinetic/pharmacodynamic characteristics of antimicrobials active against MRSA in obesepatients, especially for the target tissue. Therapeutic drug monitoring has been correlated with pharmacokinetic/pharmacodynamic optimization for vancomycin and teicoplanin, and should be used in these cases. There is more supportive evidence for the use of oxazolidinones (linezolid and tedizolid), daptomycin and lipoglycopeptides (telavancin, dalbavancin and oritavancin) in the management of SSTIs in this population. SUMMARY: The pharmacokinetic/pharmacodynamic approach, which can be used as a basis or supplement to clinical trials, provides valuable data and decision-making tools for optimizing regimens used for both prevention and treatment of SSTIs in the obese population. Important pharmacokinetic/pharmacodynamic characteristics of antibiotics, such as the penetration into the subcutaneous tissue and the probability of reaching the pharmacodynamic, target dictate efficacy, and thus should be taken into account and further investigated.
Authors: Alison L Blackman; Praneeth Jarugula; David P Nicolau; Sai Ho Chui; Manjari Joshi; Emily L Heil; Mathangi Gopalakrishnan Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: HaYoung Ryu; Sana Mohayya; Thomas Hong; Mansi Modi; Jaehee Yang; Ahmed Abdul Azim; Pinki J Bhatt; Luigi Brunetti; Navaneeth Narayanan Journal: Open Forum Infect Dis Date: 2022-02-28 Impact factor: 3.835
Authors: Christoph Dorn; David Petroff; Alexander Kratzer; Frieder Kees; Charlotte Kloft; Markus Zeitlinger; Hermann Wrigge; Philipp Simon Journal: Eur J Drug Metab Pharmacokinet Date: 2022-08-09 Impact factor: 2.569
Authors: Rodrigo M Carrillo-Larco; Cecilia Anza-Ramírez; Giancarlo Saal-Zapata; David Villarreal-Zegarra; Jessica Hanae Zafra-Tanaka; Cesar Ugarte-Gil; Antonio Bernabé-Ortiz Journal: J Epidemiol Community Health Date: 2021-07-29 Impact factor: 3.710